Filing Details

Accession Number:
0001127602-12-023278
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-31 19:35:39
Reporting Period:
2012-07-27
Filing Date:
2012-07-31
Accepted Time:
2012-07-31 19:35:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1541946 E Sean Harper One Amgen Center Drive
Thousand Oaks CA 91320-1799
Evp, Research & Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-27 1,391 $71.88 53,823 No 4 M Direct
Common Stock Acquisiton 2012-07-27 8,000 $58.43 61,823 No 4 M Direct
Common Stock Acquisiton 2012-07-27 16,109 $71.88 69,932 No 4 M Direct
Common Stock Acquisiton 2012-07-27 14,400 $69.78 84,332 No 4 M Direct
Common Stock Disposition 2012-07-27 39,900 $82.33 52,432 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Iso (Right to Buy) Disposition 2012-07-27 1,391 $0.00 1,391 $71.88
Common Stock Nqso (Right to Buy) Disposition 2012-07-27 8,000 $0.00 8,000 $58.43
Common Stock Nqso (Right to Buy) Disposition 2012-07-27 16,109 $0.00 16,109 $71.88
Common Stock Nqso (Right to Buy) Disposition 2012-07-27 14,400 $0.00 14,400 $69.78
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-04-03 2013-04-03 No 4 M Direct
16,000 2012-04-26 2020-04-26 No 4 M Direct
0 2007-04-03 2013-04-03 No 4 M Direct
0 2008-02-08 2014-02-08 No 4 M Direct
Footnotes
  1. The price reported is an average price. The prices ranged from $82.28 to $82.48 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  2. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  3. These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.